Gossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib Progress

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Gossamer Bio, Inc. is one of them.

Gossamer Bio, Inc. (NASDAQ:GOSS) is a late-stage clinical biopharmaceutical company focused on developing and commercializing seralutinib, an inhaled small molecule therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug targets multiple receptors, including PDGFR, colony-stimulating factor 1 receptor, and c-KIT, addressing high unmet medical needs in the PAH market. The company has secured licensing agreements for seralutinib and is positioning itself as a key player in this niche cardiovascular sector.

In September 2025, Gossamer Bio, Inc. (NASDAQ:GOSS)’s stock rose nearly 18% following FDA designations and positive developments in its seralutinib pipeline. The firm showcased its strategic focus on pulmonary hypertension treatments at multiple investor conferences, signaling strong growth ambitions. Management also approved inducement stock awards as part of employee incentive plans, underscoring confidence in long-term pipeline advancement, making it one of the best penny stocks to watch.

Financially, Gossamer Bio, Inc. (NASDAQ:GOSS) faces challenges with a net loss of approximately $38.3 million for the recent quarter and a negative shareholder equity position. However, gross margins remain near 100%, suggesting strong potential profitability upon commercialization. Analysts remain optimistic, with strong buy ratings. The ongoing Phase 3 PROSERA study is central to Gossamer Bio’s strategy. Seralutinib’s efficacy and safety results from this trial could support regulatory submissions and market approval, potentially opening access to an underserved PAH market.

While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.